CERvical Cancer The InFlammatory Index (CERTIFIKO)

Although significant advances in screening and treatment , cervical cancer is the fifth most common female cancer in Europe. Major prognostic factors for oncological outcome are used to categorise patients at high, intermediate and low risk groups and to define the type of radical hysterectomy according "Querleu-Morrow classification". The goal of this prospective observational study is to evaluate the association between several inflammatory markers and risk groups according European guidelines in women with cervical cancer Human Papillomavirus (HPV)-associated, in order to optimize the treatment.

Inclusion Criteria:At least 18-year-old patients.Patients histologically diagnosed with cervical cancer (squamous cell carcinoma or adenocarcinoma HPV- associated)Patients with (2018 FIGO) stage ≤ IB2 ("Early Cervical Cancer")Patients undergoing full-body CT-scan 30 days before enrollment.Exclusion Criteria:Patients unfit to pleadPatients with chronic inflammatory diseases (IBDs; rheumatic conditions)Synchronous tumors or cancer diagnosis in the previous 3 yearsPatients undergoing steroid therapy in the last 30 days prior to recruitment